Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more
Aelis Farma SA (AELIS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.635x
Based on the latest financial reports, Aelis Farma SA (AELIS) has a cash flow conversion efficiency ratio of -0.635x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.88 Million) by net assets (€6.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aelis Farma SA - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Aelis Farma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aelis Farma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aelis Farma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VVC Exploration Corporation
OTCQB:VVCVF
|
-0.017x |
|
Wolfden Resources Corporation
PINK:WLFFF
|
-0.231x |
|
Starteck Finance Limited
NSE:STARTECK
|
0.001x |
|
UDAYSHIVAKUMAR INFRA ORD (BSE)
NSE:USK
|
0.019x |
|
Precio Fishbone AB (publ)
ST:PRCO-B
|
0.004x |
|
Turnstone Biologics Corp. Common Stock
NASDAQ:TSBX
|
-0.292x |
|
Sports Entertainment Group Ltd
AU:SEG
|
0.082x |
|
Jaycorp Bhd
KLSE:7152
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Aelis Farma SA (2018–2024)
The table below shows the annual cash flow conversion efficiency of Aelis Farma SA from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €10.12 Million | €-11.83 Million | -1.170x | -22.67% |
| 2023-12-31 | €13.20 Million | €-12.59 Million | -0.953x | -44.57% |
| 2022-12-31 | €19.79 Million | €-13.05 Million | -0.659x | -103.12% |
| 2021-12-31 | €898.00K | €18.97 Million | 21.125x | +505.27% |
| 2020-12-31 | €-710.00K | €-2.48 Million | 3.490x | +245.50% |
| 2019-12-31 | €1.20 Million | €-2.89 Million | -2.399x | -61.24% |
| 2018-12-31 | €2.38 Million | €-3.55 Million | -1.488x | -- |